GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Cash, Cash Equivalents, Marketable Securities

SIGY (Sigyn Therapeutics) Cash, Cash Equivalents, Marketable Securities : $0.01 Mil (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Cash, Cash Equivalents, Marketable Securities?

Sigyn Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 ($0.17 Mil) to Dec. 2024 ($0.01 Mil) but then increased from Dec. 2024 ($0.01 Mil) to Mar. 2025 ($0.01 Mil).

Sigyn Therapeutics's annual cash, cash equivalents, marketable securities increased from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) but then stayed the same from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil).


Sigyn Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sigyn Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.34 0.01 0.01 0.01

Sigyn Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.05 0.17 0.01 0.01

Sigyn Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Sigyn Therapeutics  (OTCPK:SIGY) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Sigyn Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sigyn Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Executives
Joseph Segelman director, 10 percent owner, officer: President & CEO 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp 10 percent owner 9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman director, officer: Secretary 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212